Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI scan could replace liver biopsies

NCT ID NCT03743272

Diagnosis Sponsor: Perspectum Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on different types of scanners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LiverMultiScan (a special MRI scan)
What this could lead to
If successful, this could help doctors use a non-invasive MRI scan to reliably measure liver health, reducing the need for biopsies.
What could go wrong
This is a small, early-stage study focused on technical accuracy, not on treating disease. It may not prove that the scan works in all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

61 people

The number who actually took part.

Started

Jun 2017

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are those with mixed liver disease aetiology and those without any history of liver disease in order to represent a wide range of values of hepatic fat, iron, and fibro-inflammatory status.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any person over 18 years of age. * Participant is willing and able to give informed consent. Exclusion Criteria: * The participant may not enter the study if they have any contraindication to magnetic resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia). * Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study or affect the participant's ability to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune hepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis Cholangitis, Sclerosing cirrhosis of liver Fibrosis hereditary hemochromatosis liver disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease primary biliary cholangitis primary sclerosing cholangitis viral hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune hepatitis Cirrhosis Hemochromatosis Liver diseases Non - alcoholic steatohepatitis Non-alcoholic fatty liver disease Primary biliary cirrhosis Primary sclerosing cholangitis Viral hepatitis

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Leiden University Medical Centre

    Leiden, Netherlands

  • Southampton General Hospital

    Southampton, United Kingdom

  • University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR)

    Oxford, Oxfordshire, OX3 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.